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A B S T R A C T
We propose a flexible method for interim design modifications in
time-to-event studies. With this method, it is possible to inspect
the data at any time during the course of the study, without
the need for pre-specification of a learning phase, and to make
certain types of design modifications depending on the interim
data without compromizing the type I error risk. The method can
be applied to studies designed with a conventional statistical test,
fixed sample or group sequential, even when no adaptive interim
analysis and no specific method for design adaptations (such as
combination tests) had been foreseen in the protocol. Currently,
the method supports design changes such as an extension of the
recruitment or follow-up period, as well as certain modifications
of the number and the schedule of interim analyses as well as
changes of inclusion criteria. In contrast to existing methods
offering the same flexibility, our approach allows to make use
of the full interim information collected until the time of the
adaptive data inspection. This includes time-to-event data from
patients who have already experienced an event at the time of
the data inspection, and preliminary information from patients
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still alive, even if this information is predictive for survival, such
as early treatment response in a cancer clinical trial.
Our method is an extension of the so-called conditional rejec-
tion probability (CRP) principle. It is based on the conditional
distribution of the test statistic given the final value of the same
test statistic from a subsample, namely the learning sample. It is
developed in detail for the example of the logrank statistic, for
which we derive this conditional distribution using martingale
techniques.
Major parts of this work will be published in the Journal of the
American Statistical Association, see Irle and Schäfer (2012).
Z U S A M M E N FA S S U N G
Wir stellen eine flexible Methode vor, mit der Design-Adaptionen
in Überlebenszeitstudien vorgenommen werden können. Ein
Vorteil dieses Ansatzes ist, dass eine adaptive Zwischenauswer-
tung zu einem beliebigen Zeitpunkt während der Studiendauer
vorgenommen werden kann, ohne dass dieser vor Studienbeginn
festgelegt worden sein muss. Abhängig von den beobachteten
Studiendaten können mit Hilfe unserer Methode verschiedene
Design-Änderungen unter Wahrung des Signifiganzniveaus vor-
genommen werden. Dabei kann unser Ansatz sogar in Studien
mit optimalen fixed-sample bzw. gruppensequentiellen Designs
v
zur Anwendung kommen, in denen ursprünglich keine Zwi-
schenauswertung vorgesehen gewesen ist. Derzeit unterstützt
unsere Methode Verlängerungen der Nachbeobachtungszeit, be-
stimmte Veränderungen in der Anzahl und Terminierung der
Zwischenauswertungen sowie Veränderungen der Einschlusskri-
terien.
Im Gegensatz zu bereits existierenden Methoden, die die selbe
Flexibilität bieten, hat unser Ansatz den großen Vorteil, dass
sämtliche Patienteninformationen, die zum Zeitpunkt der Datenin-
spektion erhoben werden, für Designveränderungen genutzt wer-
den können. Dies umfasst genauso Überlebenszeitdaten von
Patienten, die zum Zeitpunkt der Dateninspektion bereits ver-
storben sind, wie sämtliche Informationen zu Patienten, die zum
Zeitpunkt der Dateninspektion noch leben - selbst, wenn diese
Informationen mit der noch nicht beobachteten Überlebenszeit
korrelieren. Mithin ist es beispielsweise in Krebsstudien möglich,
die Tumor-Response von noch lebenden Patienten als Entschei-
dungsgrundlage für eventuelle Designänderungen zu verwenden.
Die Möglichkeit, sämtliche Patienteninformationen für Design-
änderungen heranzuziehen, minimiert die Wahrscheinlichkeit
suboptimaler oder gar falscher Designadaptionen.
Unser Ansatz ist eine Erweiterung des sogenannten Condi-
tional Rejection Probability (CRP) Prinzips und basiert auf einer
bedingten Verteilung der verwendeten Teststatistik. Wir leiten
vi
diese mit Hilfe eleganter Martingalmethoden für die Logrank-
Statistik her.
Große Teile dieser Arbeit werden in der hier vorliegenden Form
im Journal of the American Statistical Association publiziert, vgl.
Irle und Schäfer (2012).
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I N T R O D U C T I O N
In the last two decades, a broad variety of adaptive test proce-
dures has been proposed that allow the adaptation of design
elements to the data collected earlier in the course of the trial,
while conserving the type I error risk, see e.g. Bauer and Köhne
(1994), Proschan and Hunsberger (1995), Lehmacher and Wass-
mer (1999), Müller and Schäfer (2004). Liu et al. (2002) developed
a unified theoretical framework for adaptive designs that broadly
established the validity of adaptation. Typical applications of
adaptive designs include data dependent variance and sample
size re-estimations. In the last decade, more complex designs and
design changes have been considered such as dropping of treat-
ment arms in multi-armed or dose finding trials, or focussing
patient recruitment on most promising patient subgroups. In gen-
eral, these so-called phase II/III combination designs combine
multiple testing procedures such as closed testing with adaptive
design methods (Brannath et al. 2009; Liu and Pledger 2005).
Schäfer and Müller (2001), Wassmer (2006), Brannath et al.
(2009) and various other authors proposed adaptive design meth-
ods for studies that employ specific test statistics for censored
1
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survival times or time-to-event endpoints. With several of these
methods, alpha inflation may still arise when predictive informa-
tion from patients still alive at the time of the adaptive interim
data inspection is used to decide upon design modifications, see
Bauer and Posch (2004) and Jahn-Eimermacher and Ingel (2009).
This is due to the fact that design modifications then are not
stochastically independent of survival times that have not been
observed yet. Therefore, these methods do not allow to fully
exploit preliminary information correlated with time-to-event of
patients still alive at the time of the interim inspection, although
this would be highly desirable in order to ensure that decisions
upon an eventual modification of the future study design are
as substantiated as possible. For example, researchers may wish
to use interim information on tumor response observable in an
early stage of a cancer clinical trial when only little survival
information has been observed yet.
Jenkins et al. (2010) have recently developed a data-adaptive
phase II/III seamless design for subgroup selection availing of
the full interim information from the patients in the learning
sample. Their method is based on a p-value combination test
combining p-values from the learning stage patients and the
validation stage patients at the end of the study. In their design,
the number of events to be observed in each of the two stages
(or the length of the follow-up periods) is pre-specified. Also Liu
and Pledger (2005) proposed an adaptive procedure for phase
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II/III combination designs that allows to use an early endpoint
for deciding upon the further design at the end of the phase II
part, and a long-term clinical endpoint for decision making at
the end of the phase III part. Their method is also based on a
p-value combination rule. It deals with continuous outcomes and
the t-statistics, not with censored survival data.
In the present paper we present a method for data dependent
design changes in survival studies, which also makes the full
interim information available for design modifications. As an
extension of the so-called conditional rejection probability (CRP)
principle of Schäfer and Müller (2001), it is a lot more flexibile
than possible approaches based on combination tests. At the
current stage of development, the method supports a variety of
design changes including the extension of the sample size, of the
follow-up period, and/or of the number of events, modifications
of the inclusion criteria and modifications of the number and
time schedule of interim analyses, as long as the first adaptive
interim analysis is not scheduled prior to the first one under the
initial design. In sum, our method has the following features:
- The study can be designed and started with a conventional
statistical test (e.g., an UMPU test) foreseen for the final analysis.
It is not necessary to use special combination tests or combina-
tion functions. This implies that our method can be applied to
make type I error conserving design changes in ongoing survival
introduction 4
studies in which no interim analysis or adaptive data inspection
had been foreseen or planned in the protocol.
- It does not require a pre-specification of the end of the learn-
ing phase, i.e., of the time point of the adaptive interim data
inspection. The decision about the end of the learning phase may
be triggered by external information such as the end of a separate
pilot study conducted in parallel, and/or it may be made de-
pending on a more or less frequent inspection of the accumulated
data. In any case, our method guarantees full control of the type
I error rate after design changes.
- When deciding on possible design changes, the researcher
is allowed to use all data collected up to the adaptive interim
inspection. Specifically, one may use survival information from
those patients who have already died before the interim inspec-
tion, as well as auxiliary information from patients who are still
alive at this time point (censored cases), even if this information
is correlated with survival time.
- The method can be applied repeatedly during the course of a
study to change the design again if this is necessary.
- It can be applied to group sequential studies designed with a
usual group sequential design and it allows for modifications of
the number and the time schedule of interim analyses and of the
alpha spending function.
To date there is no method which offers this degree of flex-
ibility and the free use of all collected interim information for
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the mentioned types of design changes. With the CRP approach
of Schäfer and Müller (2001), only the survival status and the
survival times observed at the end of the learning phase may
be used. The combination test approach of Jenkins et al. (2010)
could be extended to incorporate some of the design changes
considered in this paper. However, as this approach is based on
combination tests, such an extension will not offer the flexibility
of our CRP method concerning the time point of the data inspec-
tion (end of learning phase), the applicability to studies in which
no design adaptation had been pre-planned, and the flexibility
to change the schedule and the procedure of interim analyses.
This increased flexibility comes at the price of higher math-
ematical complexity as compared to combination tests. In fact,
it requires the calculation of the conditional distribution of the
chosen test statistic, such as the logrank statistic, conditional
upon the test statistic of a subsample of patients. Using martin-
gale techniques, we derive an approximation of this conditional
distribution for the example of the logrank statistic. This implies
that our method is based on asymptotic distribution theory when
applied with the logrank test. Existing asymptotic theory allows
to calculate the distribution of the logrank statistic conditional
upon the interim value of the test statistic at some time point, which
is different from the problem encountered here.
In Section 2, we describe our basic statistical principle. Section
3 provides the asymptotic distribution theory to apply this prin-
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ciple with two-armed studies using the logrank statistic. Section
4 contains a practical application of our method. In Section 5, we
finally conduct a simulation study of the finite sample behavior
of the logrank statistic conditional upon the full survival infor-
mation of a subsample. Additionally, we estimate the type I error
rate of the adapted procedure in the example given in Section 4.
2
A N E X T E N D E D C R P P R I N C I P L E
2.1 method
If ϕ denotes the statistical decision function defined by the initial
design of the trial, the basic idea of the CRP principle (Müller and
Schäfer, 2004) is to replace ϕ by a modified decision function ψ
representing the modified study design, such that the conditional
error probability conditionE0 (ϕ|X) = E0 (ψ|X) holds.E0 denotes
the expectation under the null hypothesis and X denotes the set of
all interim information used for making the design modification.
In the present paper, we will develop and illustrate our method
for the example of the logrank statistic and a one-sided test, for
sake of simplicity. Let Sk denote the logrank statistic calculated
at the time point of the k-th death, defined as the number of
failures in group 1 minus the sum of proportions in group 1 of
those at risk at observed failure times. By abuse of language,
we will call k the information time of the study. Then, for the
example of a study design with a one-sided fixed sample test,
ϕ = I (SK > b) and ψ = I (SK∗ > b∗), where K and K∗ denote the
total number of deaths to be observed in the initial and modified
7
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study, respectively, and b and b∗ denote the critical limits for
rejecting the null hypothesis according to the initial and the
modified study design, respectively.
Let Porig denote the total sample of patients according to the
original study design and define P ′ ⊂ Porig the subset of patients
recruited up to the interim inspection, which takes place at the
calendar time of the k0-th death among patients in Porig.
In earlier applications of the CRP principle to survival studies,
Schäfer and Müller (2001) proposed to use X = S ′k0 in the CRP
condition mentioned above, where S ′k0 denotes the logrank statis-
tic calculated in P ′ at the time of the adaptive interim inspection.
This implies that no information other than S ′k0 may be used for
design modifications. Strictly speaking, the researchers then have
to be blinded with respect to all gathered individual information
from the patients, except S ′k0 , when making the decision on the
design modification.
To overcome this restriction, the basic idea of the extended CRP
approach proposed in the present paper, in its full generality, is as
follows: The full interim information observed in all the patients
recruited up to the interim inspection, X, is made available to the
researchers for design changes. However, it may be difficult to
calculate the conditional rejection probabilities involved, E0 (ϕ|X)
and E0 (ψ|X) , because the joint distribution of X and ϕ or ψ
cannot be determined. In this case, use a suitable random vector Y
for which you can calculate the conditional expectations E0 (ϕ|Y)
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and E0 (ψ|Y) and for which E0 (ψ|Y,X) = E0 (ψ|Y) holds true.
This is the case when X is stochastically independent of ψ given Y.
Then, after the design modification, determine the final decision
function under the modified design, ψ, from the generalized CRP
condition E0 (ϕ|Y) = E0 (ψ|Y) instead of E0 (ϕ|X) = E0 (ψ|X) .
The whole procedure will keep the type I error risk α, which
is a consequence of the fundamental property of conditional
expectations:
E0 (ψ) = E0
(
E0(ψ|Y,X)
)
= E0
(
E0(ψ|Y)
)
= E0
(
E0(ϕ|Y)
)
= E0 (ϕ) = α
In the following, we will work out this extended CRP principle
for the logrank statistic. We will show that in this case Y = S ′K∗ is
suitable, i.e. the logrank statistic calculated in P ′ at the end of the
modified design, and we will derive the asymptotic conditional
distribution of Sk given the value of S ′k.
The stepwise procedure for logrank test studies is as follows:
1. Start the study with a conventional study design (called
the original study design), specifying the total number of
patients n to be recruited, the total number of deaths K
to be observed, and the critical limit b for the final test
statistic. Hence, ϕ = I (SK > b) . The numbers n and K
can be specified explicitly in the study protocol, or they
can be defined implicitly by specifying the duration of the
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recruitment phase and of the follow-up period of the last
patient.
2. During the course of the study, the data may be inspected
at any time. If a decision for a design modification is made,
identify and document the subsample P ′ of patients re-
cruited so far. Specify the modified design including the
extended total number of deaths, K∗, to be observed. The
calculation of the modified critical boundary b∗ for the final
test statistic under the modified design, SK∗ , is postponed
to the final data analysis.
3. As soon as K∗ deaths have been observed, stop the study
and determine the generalized CRP P0
(
SK > b|S
′
K
)
. Then,
determine the critical boundary b∗ for the final test under
the modified design from the CRP condition
P0
(
SK > b|S
′
K
)
= P0
(
SK∗ > b
∗|S ′K∗
)
.
Note that on the left-hand side, S ′K could formally be re-
placed by S ′K∗ because of the well-known property of inde-
pendent increments of time-sequential log-rank statistics.
4. Determine the observed value of SK∗ and reject H0 if SK∗ >
b∗.
The method can be applied again at a later point of time in
exactly the same way. Then, one has to update the sample size K
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and the subsample P ′ to incorporate all patients recruited up to
this later time point and restart with Step 2 above.
Our method can also be applied to group sequential designs
and allows for modifications of the number and time schedule of
interim analyses. However, since the overall conditional rejection
probability can only be determined at the end of the study, care
has to be taken in order to avoid interim overspending of the
conditional type I error. This will impose some limitations on
the conditional alpha spending function of the modified design.
Suppose that the original group sequential design has m interim
analyses at information times (number of events) k1, ..., km with
(one-sided, for sake of simplicity) stopping boundaries b1, ...,bm
for the test statistic Ski at time ki. Define
CRPorig(k) :=∑
i=1,...,m
I (ki 6 k) ·P0
(
Skj 6 bj ∀ j < i,Ski > bi
∣∣∣S ′kj , j 6 i) ,
which is the sum of the CRPs at all interim analyses prior to the
actual information time k under the initial design. Similarly, let
CRPmod(k) :=∑
i=1,...,m∗
I (k∗i 6 k) ·P0
(
Sk∗j 6 b
∗
j ∀ j < i,Sk∗i > b∗i
∣∣∣S ′k∗j , j 6 i)
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for the modified design. Overspending of conditional type I error
can be avoided by choosing the boundaries b∗i for the time points
k∗i under the modified design such that
CRPmod(k) 6 CRPorig(k) for all k 6 max (km,k∗m∗)
with CRPmod (k∗m∗) = CRPorig (km). In practice, this means that
the critical boundaries under the modified design are determined
such that the cumulative conditional rejection probability un-
der the modified design is smaller or equal to the cumulative
conditional rejection probability for each k.
2.2 practical implementation in clinical studies
Several precautions are in place and additional measures of study
organization and information flow must be taken for a save im-
plementation of our method, in order to avoid bias. The method
fundamentally relies on the definition of an initial design, which
must be unambigiously specified in the study protocol. This in-
cludes a precise inclusion rule defining which events contribute
to the original decision function ϕ in the sense that these events
will be used to calculate the final value of the test statistic. To
avoid bias, it is important that the same inclusion rule is applied
whether or not the study design is changed. If a design modifica-
tion is made, then the inclusion rule of the original design will
specify how to calculate the conditional rejection probability. A
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second rule (called termination rule hereafter) specifies the time
point of the final data analysis under the original and under the
adapted design.
The calculation of the CRP in case of a design extension re-
quires a third rule (called assignment rule herafter) specifying
which of the events occuring up to the end of the initial study be-
long to patients in P ′ and which belong to patients in P ′′. To this
end, the calendar time of the design change has to be prospec-
tively documented in an amendment to the study protocol, and
the set of patients enrolled so far has to be identified (called
the "learning set"). No grouped data except from this precisely
defined set of patients may be made available to people who are
involved in the decision about the design change.
Obviously, the inclusion, assignment and termination rule need
to be defined and operated using ungrouped data only. In prac-
tical operation, this should be ensured by making the related
decisions blinded with respect to treatment groups. The use of
ungrouped data implies that the test statistics are stochastically
independent from the stopping rule, which guarantees an unbi-
ased estimation of the CRP.
The termination rule can be defined by a number of events.
Alternatively, the termination rule may be defined by a calendar
time, in which case all events occuring before this calendar time
will be used for the calculation of SK. Even though the number
of events in P ′ and P ′′ up to the end of the initial study are
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random variables in this case, blinding with respect to treatment
(i.e., using ungrouped data only) as described above will again
warrant stochastic independence of these random event numbers
and the test statistics. Then, the CRP and the final test statistics
can be unbiasedly calculated conditional upon the number of
events observed until the respective calendar time, which turns
the event numbers in P ′ and P ′′ into deterministic values. In other
words, by conditioning upon the number of observed events, the
calendar time model can thus be reduced to the usual information
time model in which time is measured in terms of the total
number of events observed.
3
A P P L I C AT I O N W I T H T H E L O G R A N K T E S T
The CRP condition P0
(
SK > b
∣∣S ′K) = P0 (SK∗ > b∗ ∣∣S ′K∗) of Step
3 in Section 2.1 implies that the extended CRP principle requires
the distribution of Sk conditional on S ′k, which will be derived in
this section using martingale theory. Some of the techniques ap-
plied here have already been introduced by Sellke and Siegmund
(1983) and Olschewski and Schumacher (1986).
3.1 model and notation
In the remainder, we adapt the notation introduced by Tsiatis
(1981), Tsiatis et al. (1985) and Sellke and Siegmund (1983). Let
the positive random variable Y denote the time of a patient’s
entry into the study as measured from the study’s onset and let
X denote the latent failure time measured from entry, which is
censored on the right by a possibly infinite random variable E.
In the remainder, Z will denote the treatment indicator, which is
either zero or one, representing one treatment or the other. We
assume that Z has a mean µZ and variance σ2Z := 1/4 (balanced
design).
15
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Using the proportional hazards regression model proposed by
Cox (1972), we assume that the hazard rate λ(x) for failure at time
x is related to Z in a log linear fashion, that is λ(x|z) = λ(x)eθz,
where λ(x|z) denotes the hazard rate at time x given that the
treatment indicator Z is equal to z. Under the null hypothesis,
H0 : θ = 0, the distribution function and density function of the
failure time X is given by F(x) := P (X 6 x) and f(x) = dF(x)/dx,
respectively. The hazard rate λ(x) is equal to f(x)/
(
1− F(x)
)
and
the cumulative hazard function is denoted by Λ.
During accrual, n individuals enter the study at times Y1, Y2, ...,
Yn, assumed identically and independently distributed with the
distribution function H(y) = P(Y 6 y). This assumption guar-
antees an increased number of entries in a fixed accrual period
as the sample size increases, see Tsiatis et al. (1985, p. 366). As-
sociated with the i-th individual is the vector (Xi,Ei, Yi,Zi) (i =
1, 2, ...,n), assumed identically and independently distributed
under H0 (Tsiatis et al. 1985, p. 366).
Define the set of patients at risk at time t and age s by
R(t, s) := {i |Yi 6 t− s,Xi ∧ Ei > s}
and let
Ni(t, s) := I {Yi +Xi 6 t,Xi 6 Ei,Xi 6 s}
describe whether or not patient i has arrived and died before
time t, and that he was uncensored and of age 6 s at the time of
death.
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To test the hypothesis
H0 : θ = 0
vs.
H+1 : θ > 0, H
−
1 : θ < 0,
we employ the sequential form of the logrank statistic
Sn(t) : =
n∑
i=1
t∫
0
Zi −
∑
j∈R(t,s)
Zj
|R(t, s)|
Ni(t,ds)
=
n∑
i=1
t∫
0
Zi −
∑
j∈R(t,s)
Zj
|R (t, s)|
Mi (t,ds) ,
where
Mi (t, s) := Ni (t, s) −Λi
{
s∧Xi ∧ Ei ∧ (t− Yi)
+} .
The logrank statistic after k deaths, Sk, as introduced in Section
2 is related to the stochastic process Sn(t) by Sk := Sn
(
t(k)
)
,
where t(k) denotes the calendar time of the k-th death among
patients in Porig.
3.2 conditional distribution of the logrank statis-
tic
Let k0,K and K∗ denote the information time (number of deaths)
of the adaptive interim inspection, the final data analysis under
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the initial design and the final data analysis under the mod-
ified design, respectively, where K∗ > K. Additionally, let T
such that P
(
T > t(K∗)
)
= 1. Also define Porig := {1, ...,n} ,P ′ :={
i ∈ Porig
∣∣Yi 6 t(k0)} and P ′′ := {i ∈ Porig ∣∣Yi > t(k0)} .
Let R ′ (t, s) := R (t, s) ∩ P ′ and R ′′ (t, s) := R (t, s)∩P ′′ and note
that it is
Sn(t) = S
′
n(t) + S
′′
n(t) + S
′′′
n (t), (3.1)
where
S ′n(t) :=
∑
i∈P ′
t∫
0
{
Zi −
∑
j∈R ′(t,s)
Zj
|R ′(t,s)|
}
Mi (t,ds) ,
S ′′n(t) :=
∑
i∈P ′′
t∫
0
{
Zi −
∑
j∈R ′′(t,s)
Zj
|R ′′(t,s)|
}
Mi (t,ds) and
S ′′′n (t) :=
∑
i∈P ′
t∫
0
{ ∑
j∈R ′(t,s)
Zj
|R ′(t,s)| −
∑
j∈R(t,s)
Zj
|R(t,s)|
}
Mi (t,ds)
+
∑
i∈P ′′
t∫
0
{ ∑
j∈R ′′(t,s)
Zj
|R ′′(t,s)| −
∑
j∈R(t,s)
Zj
|R(t,s)|
}
Mi (t,ds) .
This subdivision of Sn(t) serves as the basis of the following
theorem, which is the main result of this section and which
is necessary for the concrete calculation of the CRP under the
original and under the adapted design. In the remainder, we
denote D[a,b] the space of functions on [a,b] that are right-
continuous and have left-hand limits.
Theorem 1. Let ∆i(t) := I
{
Xi < min
(
Ei, (t− Yi)
+ )} denote the
censoring indicator and let ϑ ′(t) := P(∆i(t) = 1, i ∈ P ′) and ϑ ′′(t) :=
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P(∆i(t) = 1, i ∈ P ′′) be continuous as functions in t denoting the
probability that a death can be observed before time t in P ′ and P ′′,
respectively. Then under a sequence of local alternatives H1n : θn :=
δn−
1
2 ,
1√
n
 S ′n(·)
Sn(·) − S ′n(·)
 L−→
 δϑ ′(·)/4+B ′ (ϑ ′(·)/4)
δϑ ′′(·)/4+B ′′ (ϑ ′′(·)/4)
 (3.2)
on D[0, T ] under H1,n as n→∞ with independent standard Brownian
motions B ′ and B ′′. Here, L−→ denotes convergence in distribution.
For t ∈ [0, T ], the probabilities ϑ ′(t) and ϑ ′′(t) can be consis-
tently estimated by ϑ̂ ′(t) := 1n
n∑
i=1
I {i ∈ P ′}∆i(t) and ϑ̂ ′′(t) :=
1
n
n∑
i=1
I {i ∈ P ′′}∆i(t), respectively. Thus under H0, the distribution
of
 S ′n(t)
Sn(t) − S
′
n(t)

can be approximated by
N

 0
0
 ,
 nϑ̂ ′(t)/4 0
0 nϑ̂ ′′(t)/4


on [0, T ]. This theorem can be used to calculate the conditional
rejection probabilities involved in the generalized CRP equa-
tion in Step 3 of Section 2 with Sk := Sn
(
t(k)
)
, S ′k := S
′
n
(
t(k)
)
,
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S ′′k := S
′′
n
(
t(k)
)
, and S ′′′k := S
′′′
n
(
t(k)
)
, where t(k) as defined before
denotes the calendar time of the k-th death among patients in
Porig.
For the extended CRP principle, it remains to be shown that
E0(ψ|Y,X) = E0(ψ|Y), where Y = S ′K∗ and X is the full interim in-
formation from the subsample P ′ observed at the time of the adap-
tive interim inspection. As outlined in paragraph 4 of Section 2,
this will allow us to use the data in X to decide upon design adap-
tations. As SK∗ = S ′K∗ + S
′′
K∗ + S
′′′
K∗ according to equation (3.1) and
1√
n
S ′′′K∗
P−→ 0 as shown in the Appendix, X is asymptotically inde-
pendent of SK∗ given the value of S ′K∗ , since S
′′
K∗ does not depend
on X. Therefore,
∣∣E0(ψ(SK∗)|S ′K∗ ,X) −E0(ψ(SK∗)|S ′K∗)∣∣ −→ 0, im-
plying that also X may be used for design changes without
compromizing the type I error rate (assuming an infinitely large
sample size). The second simulation experiment of Section 5
illustrates that the use of X does not cause a significant alpha
inflation (if any at all) in the example of Section 4, which is based
on a sample size that is of practical relevance.
Remark 1. According to Step 4 of Section 2, the final statistical test
under the modified design is of the form SK∗ > s∗, for some critical
limit that depends on the observed value s ′K∗ of S
′
K∗ . In other words, it
is based on the logrank statistic in the complete study sample including
the learning and the validation sample. According to Theorem 1, the test
can asymptotically be re-written as S ′′K∗ > s˜
∗ which is a usual logrank
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test in the subsample P ′′ of patients recruited after the adaptive data
inspection. Here, s˜∗ is a modified critical limit reflecting the survival
data from the subsample recruited before the adaptive data inspection,
P ′, and which is determined from the asymptotic unconditional version
of the CRP equation, P0
(
S ′′K∗ > s˜
∗) = P0 (S ′′K > s− s ′K), where s is
the critical limit of the final statistical test under the initial design and
s ′K denotes the observed value of S
′
K.
4
E X A M P L E
We illustrate our approach for an open-labelled randomized two-
stage multicenter trial investigating the effect of combined radio-
therapy plus chemotherapy treatment compared to chemother-
apy treatment alone in patients with non-small-cell lung cancer
(Schäfer and Müller, 2001).
If θ := log(λC/λE) denotes the log hazard ratio of the control
treatment (C) versus the experimental treatment (E), the null hy-
pothesis to be tested is H0 : θ = 0. The sample size of the trial was
calculated based on the assumption of 14 months median sur-
vival in the control group (chemotherapy) and 20 months in the
experimental group (chemotherapy plus radiotherapy), resulting
in a total number of k2 = 257 deaths to be observed (one-sided
α=0.025, β = 0.2, interim analysis at k1 = 193 deaths). Assuming
an exponential survival model with a recruitment period of 40
months and a follow-up of 20 months, this implies a sample
size of n = 328. The design ϕ = I
{
Ski > bki for one i = 1, 2
}
with bk1 = 16.25208 and bk2 = 16.12500 was found using nu-
merical integration. In our fictitious example, the interim look
is performed after k0 = 60 deaths, observed 23 months after
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randomization of the first patient. At this point of time, a total
number of 190 patients have been recruited. The median survial
times observed at the interim look are 13.29 months in the control
group and 18.48 months in the experimental group. This results
in an estimated log hazard ratio of log(0.719), which alone would
suggest k2 = 300 deaths to be observed. When analyzing the
progression-free survival time (PFS) on the other hand, the study
group estimated a log hazard ratio of log(0.752) and thus decides
to increase the number of deaths to be observed by ∆k2 = 143,
obtaining k∗1 = 315 and k
∗
2 = 400 under the modified design. This
implies a sample size of n∗ = 504 under the adjusted design,
which for example might be achieved by recruiting one further
participating center without extending the initial recruitment
period of 40 months. Since the estimated median survival time in
the experimental group is shorter than 20 months, the duration
of the follow-up period is not extended either. Now, ψ needs to
be determined, which here has the form
ψ = I
{
Sk∗i > bk
∗
i
for some i = 1, 2
}
.
After k1 deaths in Porig, the study group determines S ′k1 =
16.33873 and ϑ̂ ′′
(
t(k1)
)
= 33/n. As defined before, S ′k1 denotes
the logrank statistic in the subsample P ′ calculated at the time
of the k1-th death in Porig. Similarly, ϑ̂ ′′
(
t(k1)
)
is the unbiased
estimator of the probability that a death can be observed in P ′′
before the calender time of the k1-th death in Porig, as defined in
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Theorem 1. The new critical boundary bk∗1 of the first stage of the
modified design is now calculated from the equation
P0
(
Sk∗1 > bk
∗
1
∣∣S ′k∗1) = P0 (Sk1 > bk1 |S ′k1) . (4.1)
By Theorem 1, with ξ ∼ N
(
0, ϑ̂ ′′
(
t(k1)
)
/4
)
,
P0
(
Sk1 > bk1 |S
′
k1
= 16.33873
)
= P0
(
Sk1 − S
′
k1
> bk1 − 16.33873|S
′
k1
= 16.33873
)
≈ P
(
ξ >
bk1 − 16.33873√
n
)
= 0.51203.
At the time of the k∗1-th death in Porig, the study group finds
S ′k∗1 = 22.03081 and ϑ̂
′′
(
t(k∗1)
)
= 131/n∗ and is now able to
determine the new critical boundary bk∗1 . By Theorem 1 and
equation (4.1),
P0
(
Sk∗1 > bk
∗
1
∣∣∣S ′k∗1 = 22.03081)
≈ 1−Φ
(
2 · (bk∗1 − 22.03081)√
131
)
!
= 0.51203,
resulting in bk∗1 = 21.85822.
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The new critical boundary bk∗2 of the second stage of the mod-
ified design can be calculated at the time of the second data
analysis from
P0
(
Sk∗1 6 bk∗1 ,Sk∗2 > bk∗2
∣∣∣S ′k∗1 ,S ′k∗2)
= P0
(
Sk1 6 bk1 ,Sk2 > bk2 |S ′k1 ,S
′
k2
)
.
(4.2)
At the time of the k2-th death in Porig, the study group finds
S ′k2 = 21.12618 and ϑ̂
′′ (t(k2)) = 78/n. By Theorem 1 and the fact
that cov
(
Sk1 − S
′
k1
,Sk2 − S
′
k2
)
≈ n · ϑ̂ ′′ (t(k1)) /4,
P0
(
Sk1 6 bk1 ,Sk2 > bk2 |S ′k1 = 16.33873,S
′
k2
= 21.12618
)
≈ 0.37212.
At the time of the k∗2-th death in Porig, the study group finally
observes S ′k∗2 = 22.09059 and ϑ̂
′′
(
t(k∗2)
)
= 215/n∗. It is now able
to determine the new critical boundary bk∗2 of the second stage,
as bk∗1 is already known (see above): By equation (4.2),
P0
(
Sk∗1 6 bk∗1 ,Sk∗2 > bk∗2
∣∣∣S ′k∗1 = 22.03081,S ′k∗2 = 22.09059)
!
= 0.37212,
resulting in bk∗2 = 13.46469.
According to Remark 1, this example could have also been
carried out equivalently using tests of the form S ′′k > s˜
∗
k.
5
S I M U L AT I O N S T U D Y
Using R Development Core Team (2009), we calculated the empir-
ical distribution of 1√
n
{
Sn
(
t(k)
)
− S ′n
(
t(k)
)}
. Simulations were
performed under Weibull distributed survival times with two
different baseline hazards defined by the Weibull parameters
(µ,σ2) = (400, 2002) (model 1) and (µ,σ2) = (600, 3002) (model
2). In both models, we suppose a log hazard ratio θ = log(14/17)
and apply a uniform censoring distribution based on a recruit-
ment period of 1, 200 days and a follow-up period of 600 days. In
model 1, we consider
(
n,k0,k, ϑ̂ ′′
(
t(k)
))
= (50, 10, 40, 13/50) and(
n,k0,k, ϑ̂ ′′
(
t(k)
))
= (300, 60, 240, 81/300), where the two val-
ues 13 and 81 of ϑ̂ ′′
(
t(k)
)
= 1n
∑
i∈P ′′
∆i
(
t(k)
)
have been pre-deter-
mined. As defined in Theorem 1, ϑ̂ ′′
(
t(k)
)
is the observed proba-
bility that a death can be observed in P ′′ before the time point of
the k-th death in Porig. In model 2, we consider
(
n,k0,k, ϑ̂ ′′
(
t(k)
))
= (50, 10, 40, 12/50) and
(
n,k0,k, ϑ̂ ′′
(
t(k)
))
= (300, 60, 240, 48/300).
With the notation introduced in Table 1, simulations are per-
formed as follows: We resample the survival information of
patients in Porig over and over again, discarding every replica-
tion of Porig in which the observed value of ϑ̂ ′′
(
t(k)
)
does not
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correspond to the pre-determined one (see above). A total of
100.000 suitable replications of Porig is then used to estimate the
empirical distribution of 1√
n
{
Sn
(
t(k)
)
− S ′n
(
t(k)
)}
, which is then
compared with the theoretical distribution of
θ
√
nϑ̂ ′′
(
t(k)
)
/4+ B
(
ϑ̂ ′′
(
t(k)
)
/4
)
. Results are presented in fig-
ures 1 and 2. With n = 50, both distributions are already very
close, whereas accuracy is even greater for n = 300.
In a further experiment, we calculate the empirical type I error
rate of the adjusted group sequential design for the example
already studied in the previous Section 4. We assume that the
effect size θ is estimated at the time of the interim data inspection
after k0 deaths based on the observed progression-free survival
(PFS) time and that corr
(
exp(θ̂PFS), exp(θ̂OS)
)
= 0.9990, where
θ̂OS denotes the estimated effect size calculated at the time of the
final data analysis under the adapted design based on the data
from patients in P ′. A sample size extension was only made if
exp(θ̂PFS) differed from the originally assumed hazard ratio of
14/20 by more than 30%, i.e. exp(θ̂PFS) > 1.3 · 14/20. In this case,
the necessary number of additional patients was calculated on the
basis of θ̂PFS. Based on 100.000 repetitions, we found α̂ = 0.02527
with a 95%-confidence interval of [0.02433, 0.02623] under the
adapted design.
Based on the second experiment described above, we addition-
ally compare our extended CRP principle with the traditional
one introduced by Schäfer and Müller (2001) in terms of power of
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the adjusted design. As expected, the increased flexibility of the
extended CRP principle is paid by a loss in power of the adjusted
design compared to the one under the traditional CRP principle.
However, this loss in power is very small and over-compensated
in situations in which the treatment difference is relatively small
and the additional patient information not available under the
traditional CRP principle can be used to notably improve the
estimation of the log hazard ratio θ. Results are presented in
figure 3.
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Model 1, v = (50, 10, 40, 13/50).
Model 1, v = (300, 60, 240, 81/500).
Figure 1: Convergence in Model 1
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Model 2, v = (50, 10, 40, 12/50).
Model 2, v = (300, 60, 240, 48/300).
Figure 2: Convergence in Model 2
simulation study 31
Power of the adjusted design for different hazard ratios
exp(θ) = 14/me.
Figure 3: Comparison of the traditional and the extended CRP princi-
ple.
6
D I S C U S S I O N
We here present an approach for design modification in survival
studies, which makes the full interim patient information avail-
able for design changes. Based on the CRP principle, it is more
flexible than possible combination test approaches. In particular,
in contrast to combination tests, the study can be started with a
conventional statistical test, and it does not require the time point
of the interim inspection to be pre-specified, i.e. the length of
the learning phase can be chosen dependent on the data. These
advantages come at the price of higher mathematical complexity
as the distribution of the employed test statistic conditional on
the test statistic of a subsample must be known. We have derived
this for the example of the logrank test.
In its current stage of development, our approach allows the
extension of the recruitment or follow-up period, as well as
certain modifications of the number and the schedule of interim
analyses as well as changes of inclusion criteria. Further work
is needed to extend the CRP method to more complex design
changes like subgroup selection in phase II/III seamless designs,
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for which Jenkins et al. (2010) have recently developed a method
based on combination tests.
Although the CRP principle introduced here is highly flexi-
ble and can even be used to make type I error conserving de-
sign changes in ongoing studies for which no design adaptation
has been foreseen or specified in the protocol, we nevertheless
strongly recommend to make corresponding specifications in
the protocol, such as the intended time points of adpative data
inspections and the details of how the CRP principle will be
applied in the study. Moreover, we emphasize that flexible design
methods should not be a reason to reduce the efforts of a careful
planning of the trial. Design changes in ongoing trials depending
on data inspections will always imply some loss of power as
compared to the optimal design if this had been chosen from the
beginning. However, as every experienced clinical trialist knows,
the practical conduct of clincial trials and especially of long term
clinical trials rarely complies exactly with our plans. Thus, impor-
tant reasons may arise during the course of the study to change
the design due to unforeseen deviations from the assumptions
made in the planning phase. In this case, our method offers the
option to make the necessary design changes. Herby, it is a highly
flexible method and it is simple, as it can be applied to usual
statistical tests. In sum, our recommendation for a survival study
under the proportional hazards assumption would be to plan
and to start it with a sequential logrank test, at best fulfilling
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defined statistical optimality properties such as minimal expected
number of events for ethical reasons, and to implement the CRP
principle in the protocol as a method to make design changes if
this turns out to be necessary.
For an unbiased implementation of our method, unambigous
rules for the end of the study according to the original and the
modified must be documented. When the end of the study is
defined by a certain calendar date, instead of the number of
events to be observed, the set of events to be included in the
final analysis according to the original and according to the
modified design should be recorded using ungrouped data only,
i.e., blinded with respect to treatment. Whenever a design change
is made, the set of patients recruited up to this point in time
(the "learning set" P ′) must be identified and documented for an
unambiguous calculation of the condition S ′K at the end of the
study.
A
A P P E N D I X A : G E N E R A L R E S U LT S
In the following, we will briefly provide a collection of key defi-
nitions and results on stochastic processes in the space D[a,b] of
functions on [a,b] that are right-continuous and have left-hand
limits. These results are well-known and necessary for the proof
of Theorem 1 in Section 3, which will be formally shown in
Appendix B.
Definition 1. Let (Ω,A,P) be a probability space and M a metric
space. Denote B(M) the Borel σ-algebra of M. Then, X : Ω → M is
called a random element in M, if X−1
(
B(M)
) ⊂ A, see Billingsley
(1968, Chapter 1.4).
Definition 2. Denote PXn the probability measure of the random ele-
ment Xn. The sequence
(
PXn
)
n>1 is said to converge weakly against
PX on the metric space M, if
lim
n→∞
∫
M
fdPXn −→
∫
M
fdPX
for all bounded and continuous functions f :M→ R.
Definition 3. Define D[a,b] the space of functions f on [a,b] that are
right-continuous and have left-hand limits:
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1. For a 6 t < b, f(t+) = lim
s↘t
f(s) exists and it is f(t+) = f(t).
2. For a < t 6 b, f(t−) = lim
s↗t
f(s) exists,
see Billingsley (1968, Chapter 3).
Definition 4. Let Λ[a,b] denote the class of strictly increasing, con-
tinuous mappings of [a,b] onto itself with λ(a) = a and λ(b) = b.
For f,g ∈ D[a,b] let
s(f,g) := inf
λ∈Λ[a,b]
{‖f− g ◦ λ‖+ ‖λ− Id‖} ,
where ‖·‖ denotes the supremum norm. Then, s is a metric (Billingsley
1968, Chapter 3.14) and the pair (D[a,b], s) is called Skorokhod
space.
Definition 5. Let Xn,X ∈ D[a,b]. We say that (Xn)n>1 converges
in distribution to X as n → ∞ (we write Xn L−→ X), if the sequence(
PXn
)
n>1 converges weakly towards P
X according to Definition 2.
Lemma 1. Let Xn, X ∈ D[a,b]. If
• Xn
L−→ X and
• X has continuous paths,
then
(
Xn(t1), ...,Xn(tk)
) L−→ (X(t1), ...,X(tk)) for a 6 t1 6 ... 6
tk 6 b.
Lemma 2. Let Xn,X ∈ D[a,b] such that
• X has continuous paths,
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•
(
Xn(t1), ...,Xn(tk)
) L−→ (X(t1), ...,X(tk)) for a 6 t1 6 ... 6
tk 6 b and
• lim
δ↘0
lim sup
n→∞ P
 sup
|t−t ′|6δ
t,t ′∈[a,b]
|Xn(t) −Xn(t
′)| > ε
 = 0 for all ε >
0.
Then, Xn
L−→ X in D[a,b].
The proof of Lemma 1 and Lemma 2 is omitted here.
Lemma 3. Consider a sequence of processes (X1,n,X2,n, ...,Xr,n)n>1
and a vector of limiting processes (X1, ...,Xr). Then
(X1,n,X2,n, ...,Xr,n)
L−→ (X1, ...,Xr) in (D[a,b])r
if and only if
r∑
l=1
·∫
0
cl(s)dXl,n(s)
L−→
r∑
l=1
·∫
0
cl(s)dXl(s) in D[a,b]
for any bounded left-continuous step functions cl on [a,b], where
l = 1, ..., r.
Proof. See Fleming and Harrington (1991, Lemma C.3.1). o
In case that Xl,n is a semimartingale for each n, the following
Lemma gives sufficient conditions such that
·∫
0
cl(s)dXl,n(s)
L−→
·∫
0
cl(s)dXl(s):
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Lemma 4. Let (Xn)n>1 be a sequence of Rd-valued semimartingales
with decompositions Xn =Mn +An such that
sup
n>1
En([Mn,Mn](t))+En
 t∫
0
|dAn(s)|
 <∞,
each t > 0. Further assume that (Hn,Xn)
L−→ (H,X), where (Hn)n>1
is a d× k matrix process. Then,
·∫
0
Hn(s−)dXn(s)
L−→
·∫
0
H(s−)dX(s) in D[a,b].
Proof. See Kurtz and Protter (1996), Definition 7.3, equation (7.12)
and Theorem 7.10. o
B
A P P E N D I X B : P R O O F O F T H E O R E M 1
Proof of Theorem 1. First of all, note that Sn(t) − S ′n(t) = S ′′n(t) +
S ′′′n (t) according to equation (3.1). Following Sellke and Siegmund
(1983, p. 317), let Fs be the σ-algebra generated by
Yi,Ei,Zi, I {Xi 6 s} ,Xi · I {Xi 6 s} for i = 1, 2, ...
for s > 0 and let Ft,s be the sub-σ-algebra of Fs generated by
I {Yi 6 t} , Yi · I {Yi 6 t} , I
{
Xi 6 s∧ Ei ∧ (t− Yi)+
}
,
Xi · I
{
Xi 6 s∧ Ei ∧ (t− Yi)+
}
,
I
{
Ei 6 s∧Xi ∧ (t− Yi)+
}
,
Ei · I
{
Ei 6 s∧Xi ∧ (t− Yi)+
}
,Zi, (i = 1, 2, ...).
Then according to Sellke and Siegmund (1983, p. 318), Mi(t, s) is
a Ft,s-martingale in s for each fixed t. However, since the score
processes S ′n(t) and S ′′n(t) fail to be martingales in t due to the
dependence of their integrands on t, we cannot apply standard
martingale techniques directly to derive their asymptotic joint
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distribution at different values of t, such as the martingale central
limit theorem. Therefore, we define
S ′∗n (t) :=
∑
i∈P ′
t∫
0
{Zi −E(Z)}Mi (t,ds)
and
S ′′∗n (t) :=
∑
i∈P ′′
t∫
0
{Zi −E(Z)}Mi (t,ds) ,
which are both Ft,t-martingales in t (Sellke and Siegmund 1983,
p. 318), and show that under H0 the score processes S ′n(t) and
S ′′n(t) + S ′′′n (t) can be approximated uniformly in time by S ′∗n (t)
and S ′′n∗(t), respectively.
In order to apply the martingale central limit theorem to S ′∗n (t)
and S ′′∗n (t), we need to ensure that the quadratic variation of
each process grows approximately linearly in t, see Sellke and
Siegmund (1983, p. 319).
For S ′∗n (t) and S ′′∗n (t) this linear growth does not occur in the
time scale t, but under a data-dependent transformation of time:
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Let ϑ ′−1(τ) := inf {t |ϑ ′(t) = τ} and ϑ ′′−1(τ) := inf {t |ϑ ′′(t) = τ}
with ϑ ′(t) and ϑ ′′(t) defined in Theorem 1. Then,
[
1√
n
S ′∗n
](
ϑ ′−1(τ)
)
=
1
n
∑
i∈P ′
ϑ ′−1(τ)∫
0
{Zi −E (Z)}
2
Ni
(
ϑ ′−1(τ),ds
)
=
1
n
∑
i∈P ′
{Zi −E(Z)}
2
∆i
(
ϑ ′−1(τ)
)
P−→ σ2Zτ =
τ
4
for all τ ∈ [0, ϑ ′(T)] and similar for S ′′∗n and the transformation
ϑ ′′−1(τ) for all τ ∈ [0, ϑ ′′(T)], where the first equation follows
from Andersen et al. (1995, p. 84) and the second one from Tsiatis
(1981, p. 312). Hence by Rebolledo (1980, p. 273, Proposition 1),
1√
n
S ′∗n
(
ϑ ′−1(·)
)
L−→ B ′ (·/4)
and
1√
n
S ′′∗n
(
ϑ ′′−1(·)
)
L−→ B ′′ (·/4)
in D[0, ϑ ′(T)] and D[0, ϑ ′′(T)], respectively. Thus by Lemma 1 of
Appendix A,
1√
n
(
S ′∗n
(
ϑ ′−1(τ ′1)
)
, ...,S ′∗n
(
ϑ ′−1(τ ′k)
))
L−→
(
B ′
(
τ ′1/4
)
, ...,B ′
(
τ ′k/4
) ) (B.1)
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and
1√
n
(
S ′′∗n
(
ϑ ′′−1(τ ′′1 )
)
, ...,S ′′∗n
(
ϑ ′′−1(τ ′′l )
))
L−→
(
B ′′
(
τ ′′1 /4
)
, ...,B ′′
(
τ ′′l /4
) ) (B.2)
for 0 6 τ ′1 6 ... 6 τ ′k 6 ϑ ′(T) and 0 6 τ ′′1 6 ... 6 τ ′′l 6 ϑ ′′(T),
where B ′ and B ′′ are standard Brownian motions.
Lemma 5. Under a sequence of contiguous alternatives H1n : θn =
δn−1/2,
1√
n
(
S ′n
(
ϑ ′−1(τ ′1)
)
− S ′∗n
(
ϑ ′−1(τ ′1)
)
, ...,
S ′n
(
ϑ ′−1(τ ′k)
)
− S ′∗n
(
ϑ ′−1(τ ′k)
)) P−→ (δτ ′1
4
, ...,
δτ ′k
4
)
,
(B.3)
1√
n
(
S ′′n
(
ϑ ′′−1(τ ′′1 )
)
− S ′′∗n
(
ϑ ′′−1(τ ′′1 )
)
, ...,
S ′′n
(
ϑ ′′−1(τ ′′l )
)
− S ′′∗n
(
ϑ ′−1(τ ′′l )
)) P−→ (δτ ′′1
4
, ...,
δτ ′′l
4
) (B.4)
and
1√
n
(
S ′′′n
(
ϑ ′′−1(τ ′′1 )
)
, ...,S ′′′n
(
ϑ ′′−1(τ ′′l )
)) P−→ (0, ..., 0) ∈ Rl (B.5)
for 0 6 τ ′1 6 ... 6 τ ′k 6 ϑ ′(T) and 0 6 τ ′′1 6 ... 6 τ ′′l 6 ϑ ′′(T).
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Please refer to the proof of Lemma 5 below. Thus by Slutsky’s
theorem,
1√
n
(
S ′n
(
ϑ ′−1(τ ′1)
)
, ...,S ′n
(
ϑ ′−1(τ ′k)
))
L−→
(δτ ′1
4
+B ′
(
τ ′1/4
)
, ...,
δτ ′k
4
+B ′
(
τ ′k/4
) )
,
and
1√
n
(
S ′′n
(
ϑ ′′−1(τ ′′1 )
)
+ S ′′′n
(
ϑ ′′−1(τ ′′1 )
)
, ...,
S ′′n
(
ϑ ′′−1(τ ′′l )
)
+ S ′′′n
(
ϑ ′′−1(τ ′′l )
))
L−→
(δτ ′′1
4
+B ′′
(
τ ′′1 /4
)
, ...,
δτ ′′l
4
+B ′′
(
τ ′′l /4
) )
under H1n. Note that ∀ η, ε > 0 ∃ δ > 0 ∃ n0 > 1 ∀ n > n0 :
P
(
sup
|τ−τ˜|<δ
τ,τ˜∈[0,ϑ ′(T)]
∣∣S ′n(ϑ ′−1(τ))− S ′n(ϑ ′−1(τ˜))∣∣ > ε) 6 η
and
P
(
sup
|τ−τ˜|<δ
τ,τ˜∈[0,ϑ ′′(T)]
∣∣∣S ′′n(ϑ ′′−1(τ))+ S ′′′n (ϑ ′′−1(τ))
−
{
S ′′n
(
ϑ ′′−1(τ˜)
)
+ S ′′′n
(
ϑ ′′−1(τ˜)
)} ∣∣∣ > ε) 6 η
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and that δτ/4+B ′ (τ/4) has continuous paths. Hence by Lemma
2 of Appendix A,
1√
n
S ′n
(
ϑ ′−1(·)) L−→ δ · Id[0,ϑ ′(T)](·)/4+B ′ (·/4)
and
1√
n
{
S ′′n
(
ϑ ′′−1(·))+ S ′′′n (ϑ ′′−1(·))} L−→ δ · Id[0,ϑ ′′(T)](·)/4+B ′′ (·/4)
in D[0, ϑ ′(T)] and D[0, ϑ ′′(T)], respectively, where IdA denotes
the identity function on a set A.
Using Lemma 3 and Lemma 4 of Appendix A, it can finally be
shown that
1√
n
 S ′n(·)
S ′′n(·) + S ′′′n (·)
 L−→
 δϑ ′(·)/4+B ′ (ϑ ′(·)/4)
δϑ ′′(·)/4+B ′′ (ϑ ′′(·)/4)

inD[0, T ]. o
Proof of Lemma 5. According to Schoenfeld (1981), 1√
n
{
Sn(t) −
S∗n(t)
} P−→ δϑ(t)4 pointwise for t ∈ [0, T ], where
ϑ(t) = P
(
∆i(t) = 1, i ∈ Porig
)
Sn(t) as defined in Section 3.1 and
S∗n(t) :=
∑
i∈Porig
t∫
0
{Zi −E (Z)}Mi(t,ds).
These results are also true for S ′n(t) − S ′∗n (t) and ϑ ′(t) as well as
S ′′n(t) − S ′′∗n (t) and ϑ ′′(t), which immediately implies (B.3) and
(B.4). Finally, (B.5) follows from the weak law of large numbers.
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